Background

Although current guidelines recommend routine use of oral colchicine as a first-line adjunct therapy to aspirin/nonsteroidal anti-inflammatory drugs (NSAIDs) for acute and recurrent pericarditis, there are insufficient data to recommend routine use of colchicine for the initial management of myopericarditis.

Methods

The records of 194 patients who were admitted for myopericarditis were investigated retrospectively. Patients receiving oral colchicine (n = 33) as an adjunct to aspirin/NSAIDs comprised the study group and patients who received conventional therapy (n = 31) formed the control group. Plasma C‑reactive protein (CRP) levels, cardiac biomarkers, and several electrocardiographic parameters of atrial activation were evaluated before the start of treatment and at the 6‑month follow-up.

Results

Assessments before and after treatment with regard to cardiac biomarkers and plasma CRP levels showed improvements in both groups (p > 0.05). There were statistically significant improvements in P wave indices including P wave duration, PR interval length, P wave dispersion, P terminal force, and isoelectric interval in the colchicine therapy group compared with the control group (p < 0.01).

Conclusion

Routine use of colchicine for the initial management of myopericarditis as a first-line adjunct therapy to aspirin/NSAIDs in patients with myopericarditis has favorable effects on electrocardiographic indices of atrial activation parameters.

中文翻译：

---

口服秋水仙碱作为心肌心包炎一线辅助治疗的疗效

背景

尽管目前的指南推荐常规使用口服秋水仙碱作为阿司匹林/非甾体抗炎药 (NSAIDs) 的一线辅助治疗急性和复发性心包炎，但没有足够的数据推荐常规使用秋水仙碱作为肌心包炎的初始治疗。

方法

对 194 例因心肌心包炎入院的患者的病历进行了回顾性调查。接受口服秋水仙碱（n  = 33）作为阿司匹林/非甾体抗炎药辅助治疗的患者构成研究组，而接受常规治疗的患者（n  = 31）构成对照组。血浆 C 反应蛋白 (CRP) 水平、心脏生物标志物和心房激活的几个心电图参数在治疗开始前和 6 个月随访时进行了评估。

结果

治疗前后对心脏生物标志物和血浆 CRP 水平的评估显示两组均有改善（p  > 0.05）。与对照组相比，秋水仙碱治疗组的P波时长、PR间期长度、P波离散度、P末端力、等电点间期等P波指标均有显着改善（p  < 0.01）。

结论

作为肌心包炎患者阿司匹林/非甾体抗炎药的一线辅助治疗，常规使用秋水仙碱作为肌心包炎的初始治疗，对心房激活参数的心电图指标有良好的影响。